BR112012003232A2 - "uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos" - Google Patents

"uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos"

Info

Publication number
BR112012003232A2
BR112012003232A2 BR112012003232A BR112012003232A BR112012003232A2 BR 112012003232 A2 BR112012003232 A2 BR 112012003232A2 BR 112012003232 A BR112012003232 A BR 112012003232A BR 112012003232 A BR112012003232 A BR 112012003232A BR 112012003232 A2 BR112012003232 A2 BR 112012003232A2
Authority
BR
Brazil
Prior art keywords
gdf
traps
blood cell
combined use
increase blood
Prior art date
Application number
BR112012003232A
Other languages
English (en)
Other versions
BR112012003232B1 (pt
Inventor
Jasbir Seehra
Ravindra Kumar
Robert Scott Pearsall
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/583,177 external-priority patent/US8058229B2/en
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of BR112012003232A2 publication Critical patent/BR112012003232A2/pt
Publication of BR112012003232B1 publication Critical patent/BR112012003232B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112012003232-1A 2009-08-13 2010-08-13 Uso de um polipeptídeo em conjunto com um ativador do receptor de eritropoetina para aumentar os níveis de célula vermelha no sangue ou tratar anemia BR112012003232B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/583,177 US8058229B2 (en) 2008-08-14 2009-08-13 Method of increasing red blood cell levels or treating anemia in a patient
USPCT/US2009/004659 2009-08-13
PCT/US2009/004659 WO2010019261A1 (en) 2008-08-14 2009-08-13 Use of gdf traps to increase red blood cell levels
US12/583.177 2009-08-13
US30590110P 2010-02-18 2010-02-18
US61/305.901 2010-02-18
PCT/US2010/045509 WO2011020045A1 (en) 2009-08-13 2010-08-13 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Publications (2)

Publication Number Publication Date
BR112012003232A2 true BR112012003232A2 (pt) 2016-11-22
BR112012003232B1 BR112012003232B1 (pt) 2022-02-22

Family

ID=43586530

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020019169-4A BR122020019169B1 (pt) 2009-08-13 2010-08-13 Polipeptídeo
BR112012003232-1A BR112012003232B1 (pt) 2009-08-13 2010-08-13 Uso de um polipeptídeo em conjunto com um ativador do receptor de eritropoetina para aumentar os níveis de célula vermelha no sangue ou tratar anemia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020019169-4A BR122020019169B1 (pt) 2009-08-13 2010-08-13 Polipeptídeo

Country Status (14)

Country Link
EP (3) EP3838919A1 (pt)
JP (4) JP5909446B2 (pt)
KR (5) KR20180085825A (pt)
CN (7) CN105535938B (pt)
AU (1) AU2010282361B2 (pt)
BR (2) BR122020019169B1 (pt)
CA (1) CA2770822C (pt)
ES (2) ES2844123T3 (pt)
HK (2) HK1223818A1 (pt)
IL (6) IL287990B (pt)
MX (2) MX2012001916A (pt)
NZ (3) NZ712943A (pt)
RU (2) RU2592670C2 (pt)
WO (1) WO2011020045A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
CN103432568A (zh) 2005-11-23 2013-12-11 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
KR20200054317A (ko) 2007-02-09 2020-05-19 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
CN103877564A (zh) 2007-09-18 2014-06-25 阿塞勒隆制药公司 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201919685A (zh) 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
AU2010263182B2 (en) * 2009-06-12 2016-05-12 Acceleron Pharma Inc. Truncated ActRIIB-Fc fusion proteins
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2012064771A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma, Inc. Actriia binding agents and uses thereof
EP3520805B1 (en) * 2011-10-17 2021-03-10 Acceleron Pharma Inc. Compositions for treating myelofibrosis
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN112957462A (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血的方法
AU2013334659B2 (en) 2012-10-24 2019-07-11 Celgene Corporation Biomarker for use in treating anemia
KR102279522B1 (ko) 2012-11-02 2021-07-19 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
AU2015231022B2 (en) * 2014-03-21 2021-02-04 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin B and/or GDF11
TN2016000553A1 (en) * 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3212213B1 (en) * 2014-10-30 2021-04-28 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
RS64214B1 (sr) * 2014-12-03 2023-06-30 Celgene Corp Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
US20180031579A1 (en) * 2015-02-12 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
KR20180006386A (ko) 2015-04-22 2018-01-17 얼라이브젠 유에스에이 인코포레이티드 신규한 근육 소모 질환 치료용 하이브리드 ａｃｔｒｉｉｂ 리간드 트랩 단백질
EP3298034A4 (en) 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
CN108697793B (zh) 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
JP7058606B2 (ja) * 2016-02-22 2022-04-22 アクセルロン ファーマ インコーポレイテッド 増加した免疫活性において使用するためのａｃｔｒｉｉアンタゴニスト
WO2018013936A1 (en) 2016-07-15 2018-01-18 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
BR112019001615A2 (pt) * 2016-07-27 2019-04-30 Acceleron Pharma Inc. métodos e composições para tratar mielofibrose
EP3523328A4 (en) * 2016-10-05 2020-04-01 Acceleron Pharma Inc. ACTRIIB VARIANT PROTEINS AND USES THEREOF
CN116650622A (zh) 2016-10-05 2023-08-29 艾科赛扬制药股份有限公司 用于治疗肾脏疾病的组合物和方法
CN110461349A (zh) 2016-11-10 2019-11-15 科乐斯疗法公司 激活素受体iia型变体及其使用方法
CN111050770A (zh) 2017-06-14 2020-04-21 细胞基因公司 治疗骨髓增生性肿瘤相关的骨髓纤维化和贫血的方法
KR20200085832A (ko) 2017-11-09 2020-07-15 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
AU2019206634B2 (en) 2018-01-12 2024-06-27 Keros Therapeutics, Inc. Activin receptor type IIB variants and methods of use thereof
EP3790572A4 (en) * 2018-05-09 2022-03-16 Keros Therapeutics, Inc. TYPE IIA ACTIVIN RECEPTOR VARIANTS AND METHODS OF USE THEREOF
EP3873441A4 (en) * 2018-12-10 2022-06-29 Arshintseva, Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
CN111466337B (zh) * 2020-05-19 2022-04-19 山东大学齐鲁医院 一种腹主动脉瘤动物模型及其构建方法
CN115317589A (zh) * 2022-09-05 2022-11-11 中国海洋大学 脯氨酰羟化酶抑制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
DE60027135T2 (de) 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
EP1525889A1 (en) * 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
US7087224B2 (en) * 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
US20030176317A1 (en) * 2001-12-06 2003-09-18 Volkmar Guenzler-Pukall Stabilization of hypoxia inducible factor (HIF) alpha
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
JP5390070B2 (ja) * 2003-02-07 2014-01-15 プロメティック、バイオサイエンシーズ、インコーポレーテッド 赤血球形成刺激薬としての中鎖脂肪酸、グリセリド、および類似体
GB0304424D0 (en) * 2003-02-26 2003-04-02 Glaxosmithkline Biolog Sa Novel compounds
CA2574777C (en) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
BRPI0518728A2 (pt) * 2004-12-09 2008-12-02 Univ Pittsburgh vacinas para a resposta rÁpida À pandemia de gripe aviÁria
CN101198321A (zh) * 2005-04-26 2008-06-11 味之素株式会社 骨髓祖红细胞分化诱导剂
US8106176B2 (en) * 2005-10-07 2012-01-31 Instituto di Richerche di Biologia Molecolare P. Angeletti SpA Matrix metalloproteinase 11 vaccine
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100003190A1 (en) * 2006-12-08 2010-01-07 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
CA2672758C (en) * 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TW202021980A (zh) 2007-02-02 2020-06-16 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CA2729054C (en) * 2008-06-26 2019-09-03 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TW201919685A (zh) * 2008-08-14 2019-06-01 美商艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平

Also Published As

Publication number Publication date
BR122020019169B1 (pt) 2022-09-27
EP3838919A1 (en) 2021-06-23
IL275851B (en) 2021-12-01
CN105412908B (zh) 2021-08-24
JP2018177816A (ja) 2018-11-15
IL252046B (en) 2020-07-30
CN102655872B (zh) 2016-01-20
KR20180085825A (ko) 2018-07-27
IL252044A0 (en) 2017-06-29
CN105561295B (zh) 2020-03-20
IL252044B (en) 2019-11-28
KR20230003452A (ko) 2023-01-05
HK1223818A1 (zh) 2017-08-11
MX2019010341A (es) 2019-10-21
NZ623113A (en) 2015-10-30
RU2017145301A (ru) 2019-06-24
KR101882521B1 (ko) 2018-07-27
HK1224199A1 (zh) 2017-08-18
IL287990B (en) 2022-07-01
EP3117829B1 (en) 2020-10-07
EP2464369A4 (en) 2013-07-17
WO2011020045A9 (en) 2011-06-03
CN102655872A (zh) 2012-09-05
RU2642302C1 (ru) 2018-01-24
RU2012109393A (ru) 2013-09-20
JP5909446B2 (ja) 2016-04-26
CN105561295A (zh) 2016-05-11
KR20200124322A (ko) 2020-11-02
CA2770822C (en) 2020-03-24
RU2017145301A3 (pt) 2019-06-24
CN113577291A (zh) 2021-11-02
JP6860533B2 (ja) 2021-04-14
NZ598348A (en) 2014-05-30
AU2010282361A1 (en) 2012-03-15
MX2012001916A (es) 2012-05-22
ES2796121T3 (es) 2020-11-25
KR102606494B1 (ko) 2023-11-24
AU2010282361B2 (en) 2015-03-19
IL218052A (en) 2017-05-29
JP2013501816A (ja) 2013-01-17
JP2016034981A (ja) 2016-03-17
KR20120054024A (ko) 2012-05-29
CN113171442A (zh) 2021-07-27
RU2732229C2 (ru) 2020-09-14
BR112012003232B1 (pt) 2022-02-22
EP2464369A1 (en) 2012-06-20
ES2844123T3 (es) 2021-07-21
IL275851A (en) 2020-08-31
IL287990A (en) 2022-01-01
EP3117829A1 (en) 2017-01-18
JP2020203953A (ja) 2020-12-24
CN105535938B (zh) 2022-04-26
NZ712943A (en) 2017-08-25
CN113082194A (zh) 2021-07-09
WO2011020045A1 (en) 2011-02-17
RU2592670C2 (ru) 2016-07-27
KR20190111158A (ko) 2019-10-01
IL252046A0 (en) 2017-06-29
IL252045B (en) 2020-05-31
CN105535938A (zh) 2016-05-04
IL252045A0 (en) 2017-06-29
IL218052A0 (en) 2012-04-30
EP2464369B1 (en) 2020-03-11
CN105412908A (zh) 2016-03-23
RU2020127574A (ru) 2022-02-21
KR102170682B1 (ko) 2020-10-28
CA2770822A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
BR112012003232A2 (pt) "uso combinado de armadilhas gdf e eritropoietina ativadores receptor para aumentar níveis de glóbulos"
BRPI0919531A2 (pt) anticorpos contra il17 humana e usos dos mesmos
BR112013014231A2 (pt) composição de higiene pessoal e uso da composição de higiene pessoal
BRPI1011655A2 (pt) uso de lcat para tratar anemia e disfunção de glóbulos vermelhos
BRPI0910852A2 (pt) composições contendo lipídios e métodos de uso das mesmas
BRPI0813105A2 (pt) Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
BRPI0807612A2 (pt) Marcadores metabólicos de condições diabéticas e métodos de uso do mesmo
BRPI0819971A2 (pt) anticorpos contra vírus influenza e métodos de seu uso
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
BRPI0812954A2 (pt) Composição herbicidamente ativa, método para controlar vegetação indesejada, e, uso de composições
BRPI0811871A2 (pt) Composições agroquímicas ácidas bioativas e uso das mesmas
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BR112012018329A2 (pt) agentes de coloração e métodos de uso destes
BRPI1014544A2 (pt) anticorpors anti-il-17f e metodos de uso dos mesmos
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI0913833A2 (pt) uso de corantes ácidos
BR112013014235A2 (pt) anticorpos anti-ccr4 e usos dos mesmos
BRPI0809342A2 (pt) Eletrodos de bateria e baterias incluindo os referidos eletrodos
BRPI0924225A2 (pt) linhagens de células que expressam nav e métodos de uso
DK2557924T3 (da) Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.